Sensimed AG appoints David Bailey as new CEO and board member

David Bailey has managed a number of businesses in the ophthalmic field for the past 30 years, notably as chairman and CEO of Staar Surgical, Head of Surgical Business with Ciba Vision and Vice-President EMEA and Asia with Bausch and Lomb. Prior to that he served as Head of EMEA for Chiron Vision after they acquired the IOLAB ophthalmic business from Johnson and Johnson. Mr Bailey began his career in Ophthalmology as a sales representative with Johnson and Johnson. Over a ten years period he took on increasing levels of responsibility before being promoted to European Managing Director.

“I am delighted to welcome David Bailey as new CEO and Board Member of Sensimed. With his wealth of industry experience, he will be able to strongly lead the next development stages of the company. At the same time I would like to thank Jean-Marc Wismer for his valuable contributions as founding CEO of Sensimed and look forward to his continuing involvement with the company” says Erich Schlick, chairman of the company.

Says David Bailey, CEO: “I am excited to join the Sensimed team and to be involved with the SENSIMED Triggerfish technology. I believe it has the potential to radically change the way we think about Glaucoma. In measuring changes in ocular volume over a 24 hour period SENSIMED Triggerfish provides information to the physician which has never previously been available. The company has made great strides with its published peer review articles to demonstrate the accuracy and repeatability of the SENSIMED Triggerfish measurement and to begin to understand its clinical value. Our focus going forward will be to expand upon this clinical utility. I look forward to working with our highly skilled internal team along with external advisors to establish SENSIMED Triggerfish data as a key diagnostic marker in the management of this critical disease state”.

“Sensimed is very proud of having attracted someone as experienced in the field as David Bailey. The set-up of the company is ideal for the important next steps towards demonstrating further clinical utility and to bringing the SENSIMED Triggerfish device into the office of the glaucoma specialist. I much look forward to working with our new CEO towards achieving that objective” says Jean-Marc Wismer, founding director.